Brain-derived neurotrophic factor in platelet derived extracellular vesicles by Lindelöf, Anna-Emilia
 
 
 
 
 
 
 
 
 
 
 
 
Brain-derived neurotrophic factor in platelet derived 
extracellular vesicles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The University of Helsinki 
Faculty of Biological and Environmental 
Sciences 
Department of Biosciences 
Pro gradu thesis  
Biochemistry 
December 2019 
Anna-Emilia Lindelöf 
Supervisors      Pia Siljander 
Mari Palviainen 
 
  2 
 
 
Tiedekunta - Fakultet - Faculty 
Faculty of Biological and Environmental 
Sciences 
Laitos - Institution - Department 
Department of Biosciences 
Tekijä - Författare - Author 
Anna-Emilia Lindelöf 
Title 
Brain-derived neurotrophic factor in platelet derived extracellular vesicles 
Oppiaine - Läroämne - Subject 
Biochemistry 
Työn laji/ Ohjaaja - Arbetets art/Handledare - 
Level/Instructor 
Pro gradu -thesis / Pia Siljander, Mari 
Palviainen,  
Aika - Datum - Month and year 
December 2019 
Sivumäärä - Sidoantal - Number of pages 
64 
Tiivistelmä - Referat - Abstract 
Background. Platelets are known to contain ample amounts of brain derived neurotrophic factor. 
Previous spectrophotometric studies carried out in Pia Siljander’s lab have shown that BDNF is 
secreted from activated platelets packed in extracellular vesicles. For this project we wanted to 1) 
confirm that BDNF really is secreted in extracellular vesicles (EVs)2) find out how the choice of 
agonist affected the BDNF cargo of the platelet derived EVs, and 3) find out if the BDNF is packed 
into EVs of certain densities rather than others. 
 
Methods.  The platelets were isolated from platelet concentrates by size exclusion chromatography. 
The isolated platelets were then activated by thrombin and collagen co-stimulation (TC) and by 
Ca2+ionophore, respectively. The platelet activation produced extracellular vesicles (PEVs) which 
were isolated by differential ultracentrifugation. The isolated PEVs were then analysed by flow 
cytometry, ELISA and Western blot for EV typical membrane surface proteins and for their BDNF 
content. As we were interested finding out whether BDNF is enriched in PEVs to certain populations, 
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Bakgrund. Blodplättar innehåller stora mängder av proteinet brain-derived neurotrophic factor. På 
basen av tidigare spektrofotometriska studier, som utförts i Pia Siljanders laboratorium, vet vi att 
aktiverade blodplättar utsöndrar brain-derived neurotrophic factor packat i extracellulära vesiklar. 
Under detta projekt ville vi för det första, bekräfta att brain-derived neurotrophic factor utsöndras ur 
aktiverade blodplättar. För det andra, ville vi veta hur valet av agonist påverkar brain-derived 
neurotrophic factor -innehållet i de utsöndrade extracellulära vesiklarna. För det tredje, ville vi veta 
huruvida brain-derived neurotrophic factor selektivt packas i vissa populationer av extracellulära 
vesiklar. 
 
Metoder. Blodplättarna isolerades från blodplättskoncentrat med storleksseparationskromatografi. 
De isolerade blodplättarna aktiverades sedan med trombin och kollagen co-stimulation eller 
Ca2+ionofor. Aktiveringen resulterade i extracellulära vesiklar, som härstammade från blodplättar. 
Dessa extracellulära vesiklar isolerades sedan genom differentiell ultracentrifugering. De isolerade 
extracellulära vesiklarna analyserades med flödescytometri, ELISA och Western blot för både EV-
typiska membranproteiner och brain-derived neurotrophic factor. Då vi var intresserade av att få 
veta huruvida brain-derived neurotrophic factor berikas i specifika populationer av extracellulära 
vesiklar med ursprung i blodplättar utförde vi även gradientcentrifugering. Även dessa prover 
analyserades med ELISA och Western blot. Storleksdistributionen och koncentrationen av 
extracellulära vesiklar analyserades med nanoparticle tracking analysis 
 
Resultat och slutsatser. Vi fastställde att blodplättar utsöndrar extracellulära vesiklar då de 
behandlas med agonister. Då blodplättar stimulerades med trombin och kollagen co-stimulering 
resulterade det i extracellulära vesiklar med en högre koncentration brain-derived neurotrophic 
factor än då Ca2+ ionofor används som agonist. Resultaten tyder på att brain-derived neurotrophic 
factor aktivt och specifikt packas i bestämda populationer av extracellulära vesiklar. Detta kan 
exempelvis ske som en inflammatorisk respons. Enligt resultaten från gradientcentrifugeringen 
packas brain-derived neurotrophic factor i populationer av extracellulära vesiklar med en densitet 
mellan 1,112 g ml-1 och 1132 g ml-1. Dessa densiteter motsvarar en partikeldiameter under 500 
nm. Faktum att brain-derived neurotrophic factor aktivt packas i extracellulära vesiklar, som 
härstammar från blodplättar, med viss densitet och diameter är ett intressant resultat till exempel 
ur en teragnostisk synvinkel, eftersom extracellulära vesiklar sannolikt är i nyckelroll då nya 
cellbaserade terapiformer utvecklas. 
Om det hade funnits mera tid hade det varit intressant att optimera metoden för både 
gradientcentrifugering och för ELISA. Då hade processen blivit mer effektiv och mindre utsatt för 
materialförlust. Dessutom skulle resultaten vara mer pålitliga i.o.m mindre variation inom analysen. 
Intressant vore också att pröva hur olika agonister påverkar koncentrationen brain-derived 
neurotrophic factor i extracellulära vesiklar, som härstammar från blodplättar. Faktumet att brain-
derived neurotrophic factor aktivt packas i extracellulära vesiklar, som härstammar från blodplättar 
med viss densitet och diameter är ett intressant resultat till exempel ur en teragnostisk synvinkel, 
eftersom extracellulära vesiklar sannolikt är i nyckelroll då nya cellbaserade terapiformer utvecklas. 
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1. Background 
1.1 Platelets 
 
Platelets originate from megakaryocytes in the bone marrow, in blood vessels, and also in the lungs 
(Figure 1, Lefrançais & Looney 2019). The megakaryocyte is a polyploid hematopoietic cell. Polyploid 
megakaryocytes and anucleate platelets can only be found in mammals. The human body produces 
1*1011 platelets every day and their lifespan in the blood circulation is 8-10 days. The ageing platelets 
are then eventually phagocytosed by macrophages in the spleen. The diameter of resting platelets is 
2-4 µm and they are discoid in shape. It had been shown by means of flow cytometry, histogram and 
single cell analytics, that platelet populations differ from each other in both volume density as well as 
reactivity (Baaten et al. 2017). 
 
Platelets are produced by pinching off from the cytoplasm of megakaryocytes (Radley and Haller 1982). 
Due to this process platelets do not contain any DNA. All platelets do, however, contain plenty of 
proteins (Burkhart et al. 2013), mRNA (Laffont et al. 2013) and microRNA (Baaten et al. 2017). This 
platelet cargo is then secreted following platelet activation. The environment of the developing 
megakaryocyte affects the properties of the platelet that pinches off from it. The platelet 
transcriptome of a person suffering from systemic lupus erythematosus, for instance, differs from that 
of a healthy control subject (Lood et al. 2010). 
 
Megakaryocytes also contain growth promoting cytokines, such as interleukin 3 (Machlus & Italiano 
2013), thrombopoietin (Machlus & Italiano 2013) and brain derived neurotrophic factor (BDNF) 
(Chacón-Fernández 2016). Platelets are known to perform protein synthesis (Ludány and Kellermyer 
1988) but megakaryocytes appear to be the primary source of the BDNF stored in platelets. This seems 
plausible, since megakaryocytes contain an easily detectable amount of BDNF (Chacón-Fernández et 
al. 2016). The theory is further supported by the fact that BDNF, in both megakaryocytes and platelets, 
is stored in alfa-granules (Maynard et al. 2007). Furthermore, BDNF has been detected in pro-platelets 
(Chacón-Fernández et al. 2016) making it seem probable that platelets contain BDNF already as they 
are pinching off from megakaryocytes.  
 
A defining structural property of the platelet is an internal membrane system, the open canalicular 
system (OCS). The OCS consists of a network of channels that are connected to the platelet membrane. 
During platelet activation, the OCS partly fuses together with the platelet membrane, thus increasing 
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the membrane area to volume ratio (Escolar et al. 1989, Wachowicz et al. 2016). The OCS enables an 
effective internalization of surrounding molecules into the platelet. The OCS also provides membrane 
surface for morphological changes and it is central in the formation of extracellular vesicles (EV).  
 
The molecules that are secreted by platelets are located in intracellular vesicles that are called granules 
(Figure 1). Three different kinds of granules can be distinguished –alfa- and delta-granules as well as 
lysosomes. The most abundant granule of the three is the alfa-granule of which 50-80 typically reside 
within one platelet (Frojmovic and Milton 1982). The alfa-granules are packed with molecules 
important for haemostasis (Figure 1), such as von Willebrand factor (vWF), CD62P and integrin allb3 
(Wachowicz et al. 2016) that are secreted when the OCS fuses together with the plasma membrane. A 
tell-tale sign of platelet activation is the appearing of granular proteins, such as CD62P, to the platelet 
plasma membrane. Platelet activation precedes platelet aggregation as well the secretion of EVs.  
 
 
Figure 1 Schematic picture of the platelet displaying alpha and delta granules as well as lysosomes, 
mitochondria and the open canalicular system, which are the source of protein cargo to be packed into 
platelets. 
 
The content of the alfa-granules is heterogenous and many molecules have opposing function. The 
content can be divided, for instance, into pro- and anti-angiogenic molecules. The vascular endothelial 
growth factor (VEGF) and the platelet derived growth factor (PDGF) are examples of pro-angiogenic 
compounds (Kaplan et al. 1979), whereas endostatin (Ma et al. 2001) and angiostatin (Jurasz et al. 
2003) are examples of anti-angiogenic molecules contained within the inactive platelet. On the other 
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hand, the content of alfa-granules can also be classified as either pro- or anticoagulant (Blair and 
Flaumenhaft 2009) as well as pro- and anti-inflammatory (Golebiewska and Poole 2015) . 
 
Besides alfa-granules, the platelets contain so called delta-granules that are rich in calcium, ADP, ATP, 
serotonin and histamine, as well as pyro- and polyphosphates (Meyers et al. 1982). All of these 
molecules, within the delta-granules, are known to support platelet aggregation, the tonus of the 
vasculature and the clotting of blood (Ambrosio and Di Pietro 2017). The functionality of the third class 
of granules in platelets, the lysosome, is not yet well understood. It is, however, clear that unlike in 
other cell types, the platelet lysosomes also participate in secretion (Yadav and Storrie 2016). 
Furthermore, it appears that the lysosomal molecules participate in thrombus formation and 
remodelling of the extracellular matrix (Yadav and Storrie 2016). Platelets are also known to be an 
important source of mitochondria in the blood (Koupenova et al. 2018). These functionally diverse 
molecules can all be secreted from platelets packed into EVs. These EVs, are secreted from platelets 
as a result of an appropriate stimulus. Depending on the stimulus, these molecules then take part in a 
multitude of mechanisms. Molecules such as vWF, fibrinogen and CD62P support haemostasis by 
participating in the coagulation cascade. Molecules such as histamine, on the other hand, participate 
in immunological reactions, such as the inflammatory response (Ramadan et al. 2015). 
 
The primary function of platelets is to support the haemostatic reactions by maintaining the integrity 
of the blood vessels, and by participating in the activation of the coagulation cascade (Xu et al. 2016a) 
and profibrinolysis (Gue and Gorog 2017). Inactive platelets circulate within the blood circulation close 
to the walls of the blood vessels. An intact endothelial tissue provides a natural barrier against 
thrombosis and as such effectively hinders untimely platelet activation. The endothelium also secretes 
inhibitory factors, such as nitric oxide and prostacyclin, further supporting the inactive state of the 
platelets (Golebiewska and Poole 2015). Besides this main function, platelets also play an important 
part in both physiological and pathological processes, such as chronic inflammation, the immune 
response and in perturbances of the central nervous system, such as multiple sclerosis and Alzheimer’s 
disease (Xu et al. 2016b). 
 
Platelets may be activated by a discontinuity in the endothelial monolayer of the vasculature (Figure 
2), and by an inflammation that irritates the endothelium (Ali et al. 2015, Sonmez and Sonmez 2017). 
As the underlying matrix is revealed, disrupting the monolayer, platelets are able to interact with the 
revealed adhesive proteins. These adhesive molecules include von Willebrand factor, collagen and 
soluble platelet agonists, such as thrombin of the coagulation cascade rewieved in Wachowicz et al. 
2016. The interaction between platelets and the adhesive proteins of the subendothelium results in 
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the secretion of activating factors, such as vWF, that can further activate the platelets (Wachowicz et 
al. 2016). Platelets can alternatively be activated directly by the effect of agonists, such as thrombin 
and collagen, where the following auto-activation through secretion amplifies the response. Activated 
platelets secrete soluble cytokines and chemokines from their internal stockpile and in doing so attract 
more platelets to the site of injury to be activated (Golobiewska and Poole 2014). In this way 
aggregated platelets can ultimately result in a blood clot (Figure 2). Platelet activation also results in 
secretion of platelet derived EVs (PEV), one of the hallmarks of the activated platelet (Siljander 2011). 
 
 
Figure 2. Different phases of platelet activation in the blood circulation from resting state to 
microvesiculation, when PEVs are secreted. Adapted from Siljander 2000. 
 
Platelets and platelet rich plasma (PRP) are used to treat cancer patients, patients who have lost 
copious amounts of blood, surgery patients and for treating thrombocytopenia i.e. the condition 
where the concentration of platelets in the blood circulation is too low. PRP is also administered in 
order to support cell division and angiogenesis in bone healing processes, for instance (Agahaloo et al. 
2002, Schliephake 2002). 
 
1.2 Brain-derived neurotrophic factor 
 
Brain derived neurotrophic factor (BDNF) is a member of the nerve growth factor family. Other 
members of this family include nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4 
(Castrén and Lindholm 1992). BDNF is a basic cytokine, soluble and ball like homodimer (Barde et al 
1982, Dechant 2013). The hallmark of the protomer is a structure supported by disulfide bridges, 
typical of neurotrophins, known as cysteine knot (MacDonald et al. 1991). The cysteine knot has later 
been recognized in platelet-derived growth factor (PDGF), for instance, and in other secreted proteins 
as well (MacDonald and Hendrickson et al. 1993). The cysteine knot is also a typical structure for 
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cytokines and immunomodulative molecules (Lyer and Acharya 2011). A molecule containing a 
cysteine knot typically acts as a ligand that binds to a membrane receptor. 
 
As hinted to by its name, BDNF is amply found in the central nervous system (CNS). There it significantly 
affects embryonal neural development, neuroplasticity and in adulthood also the function of memory 
(Bibel and Barde 2000). BDNF has also been shown to be key to cardiovascular development (Pius-
Sadowska and Machaliński 2017). BDNF is synthesized within the endoplasmic reticulum as a precursor 
protein of 32-35 kDa known as prepro-BDNF (Kowianski et al. 2018). The prepro-BDNF is then cleaved 
as it is transported through the Golgi apparatus and the trans-Golgi network. ProBDNF is sorted into 
transport vesicles under the influence of carboxypeptidase E and the vesicles are then actively secreted 
from the postsynaptic dendrites (Klein et al. 1991). The terminal domain of proBDNF is finally 
enzymatically cleaved off by a protein convertase which produces a biologically active BDNF molecule 
of 14 kDa (Serra-Milàs 2016).  
 
As predicted by the cysteine knot motif, the neurotrophins bind to two transmembrane proteins – 
tropomyosin receptor kinase (Trk) and the p75 receptor that is a member of the tumour necrosis factor 
family (Figure 3). As such the neurotrophins are able to activate cells of diverse functionalities through 
ligand receptor interaction. Binding of a ligand to p75 can, for instance, transmit a signal initiating cell 
death, whereas binding to the Trk receptor stimulates cell proliferation (Bibel and Barde 2000). 
 
  
Figure 3 The two transmembrane proteins that the neurotrophins bind to i.e. the p75 and the Trk 
receptors. Adapted from Bibel and Barde 2000 and Protein Data Bank Europe. 
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The largest quantities of BDNF are found in the central nervous system (Tamura et al. 2011). BDNF is, 
however, also expressed in other tissues, such as the pancreas, the liver, the thyroid gland, the heart 
and the lungs as well (Ernfors et al. 1990, Maissonpierre et al. 1991). Monocytes, lymphocytes and 
eosinophils of the immune system also produce BDNF (Kerchensteiner et al. 1999). The production of 
BDNF in monocytes and lymphocytes is known to be of importance in protecting the nervous system 
(Kerchensteiner et al. 1999), whereas eosinophils produce and utilize BDNF to generate and maintain 
an allergic response (Raap et al. 2005). Interestingly immune cell derived BDNF has also been shown 
to support the survival and growth of cancer cells as well as the development of chemoresistance (Yang 
et al. 2006). 
 
As noted previously, BDNF is also stored in platelets (Fujimura et al. 2002). The BDNF content within 
platelets is within range of the concentration in serum and higher, in fact, than the concentration in 
the brain (Chacón-Fernández et al. 2016). The BDNF concentration in serum is ten times higher than 
that of plasma (Chacón-Fernández et al. 2016). This is due to the fact that platelets secrete BDNF during 
coagulation (Tamura et al. 2010). Platelets store up to 90% of the BDNF in our blood and the 
distribution of BDNF between the platelet cytoplasm and the alfa-granule is 70:30 (Fujimura et al 2002, 
Tamura et al. 2011). The BDNF within the alfa-particles is secreted upon activation and the rest of the 
BDNF remains within the cytoplasm of the platelet (Tamura et al. 2011). When thrombin binds to the 
protease activated receptor 1 (PAR1) it generates a cascade that finally results in BDNF secretion 
(Tamura et al. 2011). VEGF and endostatin are also similarly secreted following appropriate PAR1 
activation (Etulain et al. 2015). In other words, it seems likely that BDNF secreted by platelets amongst 
other things takes part in repairing Trk B-expressing damaged tissue (Fujimura 2002). Additionally, low 
BDNF concentration in serum have been observed and linked to serious depression (Shimizu et al. 
2003, Serra-Millàs et al. 2011), Alzheimer’s disease (Laske et al. 2007) and anorexia nervosa 
(Monteleone et al. 2005) as well as coronary heart disease (Amadio et al. 2019). 
 
The calcium-induced activation of platelets and neuron bears great resemblance. Following activation 
both secrete neurotransmitters (Ponomarev 2018). Platelets chiefly secrete the monoamine serotonin 
and in smaller amounts biogenic amines, such as epinephrine, dopamine and histamine (Ponomarev 
2018). Platelets also secrete the inhibiting neurotransmitter gamma-aminobutyric acid (GABA). GABA, 
however, is secreted in lesser amounts than the biogenic amines (Kaneez and Saeeb 2009). Not unlike 
postsynaptic nerve cells immune cells, such as CD4-positive T cells, express ample amounts of 
receptors for neurotransmitters (Levite 2016, Bode and Duerschmied 2017). As such, platelets are able 
to directly communicate with helper T cells. Platelets, T cells and the synapses of nerve cells are also 
able to interact directly with antigen presenting cells via adhesion molecules and integrins (Starossom 
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et al. 2015, Xu et al. 2016a, Zamora et al. 2017). Some of these adhesion molecules, such as neural cell 
adhesion molecule (NCAM) or CD56, are expressed by both nerve cells and a subgroup of activated T 
cells, whereas others, such as activated leucocyte adhesion molecule (ALCAM), are expressed by nerve 
cells, activated T cells as well as by platelets (Ponomarev et al. 2018). 
 
As the activation of both platelets and neurons share such striking similarities, it is safe to say that 
platelets are cells of importance, both immunologically and neuronally. This and the property of 
platelets to both store and secrete BDNF is a reason to investigate the role of platelets further in both 
immunological and neuronal research. 
 
1.3 Extracellular vesicles 
 
Most cells secrete lipid membrane enclosed vesicles that are known as EVs and they have been found 
in all biological fluids (Mathieu et al. 2019). The lipid membrane and cytoplasm of EVs is rich in 
biomolecules from the cell, from which the EV originates (van Niel et al. 2018). The amount of EVs, 
secreted by cells, increases by cell activation (Pasquet et al. 1996), oxidative cell stress (Mancek-Keber 
et al. 2015), hypoxia in the tissues (Umezu et al. 2014) and finally as a result of pathological conditions 
(Yañez-Mó and Siljander et al. 2015).  
 
EVs contain DNA, RNA, lipid and protein (Gézsi et al. 2019). Information about the molecular properties 
of EVs are comprehensively documented in open databases, such as Vesiclepedia 
(www.microvesicles.org/) (Kalra et al. 2012), EVpedia (www.evpedia.info) (Kim et al. 2013) and 
ExoCarta (www.exocarta.org) (Simpson et al. 2012). By transporting these biomolecules from one cell 
to another, EVs are able to affect the functions of the recipient cell. EVs participate in several essential 
physiological phenomena and events, such as intercellular signalling, immunity, development and 
differentiation (Yañez-Mó and Siljander et al. 2015). They are also involved in the development and 
progression of pathophysiological states, such as cancer, neurodegenerative disorders and HIV/AIDS 
(Gould and Raposo 2013, Matieu et al. 2019). EVs have been isolated from most bodily fluids including 
plasma, cerebrospinal fluid, urine, saliva and human milk (Gézsi et al. 2019, Mathieu et al. 2019).  
 
EVs are a heterogenous population of vesicles of different subcellular and biogenetic origin and, as 
such, their size, membrane structure and content are dynamic and also dependent of the cell of origin 
(Bebelman et al. 2018, Harada et al. 2019). Attempts have been made to classify EVs according to size, 
density, morphology, lipid and protein composition as well as according to subcellular origin (Akers et 
al. 2013, Figure 4). Up to date, however, it has not been possible to build up a scientifically 
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comprehensive and acceptable classification system (Théry et al. 2018). This is due to the fact that 
current isolation methods cannot separate pure vesicle populations (Mathieu et al. 2019), and on the 
other hand, since there are no specific markers for subpopulations of EVs (Théry et al. 2018, Gézsi et 
al. 2019).  
 
One of the more frequently employed means of classification is categorizing EVs according to how they 
are formed. The first group in this classification system is exosomes. They develop from the endosomal 
route within multivesicular bodies and are released as the multivesicular body fuses with the cell 
membrane (Akers et al. 2013, Figure 4). According to this classification system the second group of EVs 
are the microvesicles (Akers et al. 2013, Figure 4). Microvesicles are also known as ectosomes and 
microparticles. They form from outwards budding and fission of the cell membrane (Al Nedawi et al. 
2009, Figure 4). Apoptotic bodies make up the third group of EVs. Apoptotic bodies are freed as 
fragmentous structures following the blebbing of the cell membrane of the apoptotic cell (Jiang et al. 
2017). Apoptotic bodies are not relevant for the scope of this thesis, as the focus is on EVs derived 
from activated platelets. As such, apoptotic bodies won’t be further discussed. This classification 
system has its challenges, as it has been shown that T cell -derived exosomes, for instance, form in the 
same way as microvesicles (Lenassi et al. 2010). On the other hand, exosomes in general have a 
diameter of 30-100 nm, but they are also known to sometimes have a diameter above 100 nm. The 
diameter of microvesicles is 100-1000 nm, however, microvesicles are also known to sometimes have 
a diameter that is more than 1000 nm. In other words, size alone cannot be used to classify EVs.  
 
As the classification system is not unambiguous and the size classes of the subgroups are partly 
overlapping, I will use the umbrella term EV in this thesis, without specifying which subgroup I might 
be referring to. This is a practice also recommended by the foremost organization for professionals 
working with EVs, the International Society of Extracellular vesicles (ISEV) (Théry et al. 2018). 
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Figure 4 The biogenesis, subcellular origin and size groups of EVs and their release into the extracellular 
space. Adapted from Yañez-Mó and Siljander et al. 2015 
 
EVs are secreted from the membrane of activated and apoptotic cells. Inactive cells are also, however, 
known to secrete small amounts of EVs (Kalra et al. 2016). The amount of EVs in the blood flow of a 
healthy person is at a dynamic relatively steady state (Yañez-Mó and Siljander et al. 2015). In other 
words, there is a balance between the secretion and clearance of EVs from the blood flow in a healthy 
body. EVs are known to express surface proteins, such as CD55 and CD59, that are anchored to the 
membrane by the glycolipid glycosylphosphatidylinositol (GPI). It is likely that EVs protect themselves 
from complement mediated lysis by expressing these surface proteins (Clayton et al. 2003). Thus, EVs 
are removed from the blood circulation either through the spleen (Davila et al. 2008), through 
phagocytosis by other cells (Delabranche et al. 2012), dissolved by lipases (Haggadone and Peters-
Golden 2018) or by reaching the target organ, where they end up delivering their message to the cells 
(Jiang et al. 2017). When investigating the biodistribution of EVs from red blood cells, for instance, it 
has been found that 44.9% end up on the liver, 22.5% end up in the bone tissue, 9.7% end up in the 
epidermis and 5.8% in muscle tissue (Willekens et al. 2008). 
 
As EVs are such a diverse population it has not been possible to determine an overall half-life for EVs 
in general. The clearance of EVs from different sources has been under a lot of investigation. The 
clearance of red cell-derived EVs has been determined as 30 minutes, for instance (Willekens et al. 
2005). When investigating the clearance of PEVs, however, the results have shown great variation. The 
half-life for EVs expressing phosphatidylserine (PS+) on the cell membrane derived from platelets 
activated by calcium ionophore has been determined to be less than 10 minutes (Rand et al. 2006). 
The clearance of PEVs in the blood of patients, who have received a blood transfusion, on the other 
hand, has been determined to be more than three hours (Rank et al. 2011). Both of these studies were 
focused on PS+ PEVs, however, and the clearance of PS- PEVs is yet to be determined. 
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Besides expressing surface proteins protecting EVs from complement mediated lysis, EVs also express 
molecules on their cell membrane that enable them to target, communicate and exchange materials 
with their target cell. The mechanisms by which EVs affect their target cell is comprehensively 
discussed in the review article by Tkach and Théry (2016). According to this review, EVs are able to 
initiate a messaging cascade by delivering a ligand that then interacts with an appropriate receptor on 
the target cell. On the other hand, EVs are also delivered into the cell by either endocytosis or 
phagocytosis. EVs are also able to fuse with the cell membrane and deliver their message that way. 
Within the cell EVs then either fuse with a lysosome or with the endocytic membranes where they 
unload their cargo. As EV related research is developing at a high pace, it seems likely that new 
mechanisms of EV mediated intercellular communication is yet to be discovered. For instance, it was 
shown, somewhat recently, that a nanotube like connection is necessary in the process of intercellular 
EV mediated mRNA trafficking (Haimovich et al. 2017). 
 
When EV research was in its infancy it was thought that the function of these vesicles was in cellular 
garbage disposal. As EV research has progressed it has been shown however, that EVs do in fact have 
a plethora of important functions, in addition to taking care of cellular waste products. Cellular waste 
in this context stands for factors useless or downright harmful to the cell. For instance, as a reticulocyte 
matures to a mature erythrocyte EVs actively transport useless transferrin receptors out from the cell 
(Johnstone et al. 1989). On the other hand, the development and progression of malignant cancers is 
aided by the secretion of EVs with immunosuppressive properties (Wieckowski et al. 2009, Bobrie et 
al. 2012, Chow et al. 2014) and by actively transporting cytotoxic medications, such as doxorubicin and 
ciplactine, out of the tumour (Shedden et al. 2003, Safaei et al. 2005). In recent years neuron-derived 
EVs have also been investigated when trying to decipher CNS-related pathologies from blood biopsies 
(Saeedi et al. 2019). 
 
By transporting proteins, such as enzymes and ligands, from cell to another EVs are able to affect the 
phenotype of the recipient cell quite rapidly. EVs have also been shown to transport cargo bearing a 
longer lasting and powerful effect. EVs transport mRNA and micro-RNA from one cell to another (Valadi 
et al. 2007). The gene expression of a cell can be turned off by an EV mediated small interfering RNA 
(Alvarez et al. 2011).  
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1.4 Platelets and extracellular vesicles 
 
Most of the EVs in the blood circulation in a human body are platelet derived (Arraud et al. 2009). 
Other cells that secrete EVs into the circulation include megakaryocytes (Flaumenhaft et al. 2009), 
leucocytes (Pugholm et al. 2016), erythrocytes (de Vooght et al. 2013), endothelial cells (Curtis et al. 
2013), smooth muscle cells (Cornelli et al. 2013) and cancer cells within the blood (Raimondo et al. 
2015). Particles with procoagulant properties in plasma were first reported in 1946 (Chargaff and West 
1946). These particles, PEVs, were first seen by electronmicroscopy in 1967 (Wolf 1967) and a few 
years later the process of platelet vesiculation was demonstrated (Warren et al. 1972). PEV and EV 
research really took off as late as in the early 2000s. 
 
Platelets are enclosed by a phospholipid bilayer. This bilayer consists of PS, phosphatidylethanolamine 
(PE), phosphatidylcholine (PC), and sphingomyelin (SM) (Lhermusier et al.2011). When the platelet is 
inactive the phospholipids of the membrane are arranged in an asymmetrical fashion. This is a central 
property cell physiologically speaking and it regulates the passage into and out from a cell, for instance. 
As such, this asymmetry is actively maintained. PC and SM typically reside on the outer membrane, 
whereas, PS and PE are found on the inner membrane (Lhermusier et al. 2011). The asymmetry is 
maintained by a set of enzymes, such as, aminophospholipid translocator, scramblase, calpain, and 
gelsolin (Piccin et al. 2007, Lhermusier et al. 2011). These enzymes transport aminophospholipids to 
the inner membrane and phospholipids to the cell surface. During PEV formation and secretion, this 
asymmetry is typically disrupted and negatively charged phospholipids, such as, PS and PE are revealed 
on the cell membrane surface (Antwi-Baffour et al. 2015). This reorganization of the phospholipids 
supports the coagulation cascade, for instance, since PS strongly binds to coagulation factors and 
coagulation factor receptors, thus supporting the progression of the formation of a thrombus (Wang 
et al. 2018). 
 
The processes and molecular factors resulting in EV and PEV secretion are still somewhat unclear. It 
has been shown that in vitro PEVs are secreted as a result of both platelet activation and cell death, 
the stimuli being either chemical, as is the case with cytokines and endotoxins, or physical, as is the 
case with shear stress (Zaldivia et al. 2017). It is known, however, that EVs either pinch off from the 
cell membrane or fuse with the cell membrane together with multivesicular bodies. Thus, the secreted 
EVs carry on their surface or in their cytoplasm antigens or combinations of antigens typical of the cell 
of origin (Barry and Fitzgerald 1999). Consequently, since PEVs are secreted from the membrane of 
activated platelets, they express antigens typical for platelets and are thus recognizable as platelet 
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derived (Żmigrodzka 2016). Besides antigens and organelles, PEVs also transport a plethora of 
cytokines, enzymes, nucleic acids, and even transcription factors (Todorova et al. 2017, Zaldivia et al. 
2017). There is, in fact, such a great correlation between the nucleic acids in platelets and those in 
PEVs that it seems likely that PEVs are a significant source of RNA in the circulation (Ray et al. 2007, 
Lindsey et al. 2016). 
 
PEVs interact with the recipient cell either in a direct or in indirect way. A direct interaction indicates 
a situation where the EV is in itself the agent, as is the case when EVs function as a catalytic surface in 
the activation of coagulation factors (Kapustin and Shanahan 2016). An indirect interaction, on the 
other hand, indicates a situation where the recipient cell reacts to the message transmitted by the EV 
by changing its phenotype (Vajen et al. 2017). 
 
PEVs develop in a manner somewhat different than EVs in general. This is because of the alfa-granules 
residing within the platelet. The multivesicular body, where the exosomes develop, are thought to be 
early forms of the alfa-granules (Heijinen et al. 1998). It is also thought that they secrete exosomes by 
fusing with the platelet membrane (Heijinen et al. 1999, van Nispen tot Pannerden et al. 2010). This 
hypothesis is supported by the fact that several molecules typical of alfa-granules have been 
discovered on the membrane of PEVs (Aatonen et al. 2012). One example is the protein CD63 which is 
a typical exosome associated protein (Gao et al. 2018). In PEVs, CD63 is also enriched in the 
microvesicles (ven der Zee et al 2006). On the other hand, proteins typical for microvesicles have also 
been found in and on platelet derived exosomes (Heijinen et al. 1999). Distinguishing the different 
subpopulations from each other is difficult to begin with and when working with PEVs it is that much 
harder. Surface proteins such as PCAM-1, CD62P (P selectin), CD63 and CD41 are typical for PEVs 
(Aatonen et al. 2014) making them useful when investigating PEVs. They are, however, not enough for 
an undisputed identification. When working with EVs it is recommended and important to validate the 
findings using a wide enough selection of criteria and methods (Théry et al. 2018). This holds true for 
PEVs as well. The characteristics and requirements for high-class EV research is an ongoing discussion 
in the EV community (Lötvall et al. 2014, Wittmer et al. 2017, Théry et al. 2018). 
 
Platelets secret small amounts of PEV when they are unstimulated (Zaldivia 2017). In order to gain 
enough platelets for scientific research, however, platelets need to be activated. Platelets can be 
activated by subjecting them to shear stress, such as vigorous shaking (Zaldivia 2017), or by treating 
them with agonists, such as collagen, thrombin and calcium ionophore (Siljander et al. 1996). 
Activation by thrombin and collagen mimics the initiation of the haemostatic / thrombotic cascade, 
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whereas calcium ionophore mimics a general initiation of EV secretion independent of cell type as it is 
based on a rise in the intracellular calcium concentration (Siljander et al. 1996). 
 
1.5 Isolating extracellular vesicles. 
 
Although the theme of this thesis is not the isolation methods of EVs, I want to briefly discuss the topic, 
since the methods of EV isolation may significantly affect the outcome of any EV-related project.  
 
The interest the science community has towards EV related research is blooming and the hopes for 
health-related application of the results are finally being realised. EVs are isolated for research 
purposes in many different ways and these methods are often quite poorly standardised (Coumans et 
al. 2017). In order for research results to be comparable to other each other, reproducible and 
applicable, considerable effort still needs to be devoted to the development of efficient methods of 
isolation and analysis. 
 
Of our bodily fluids, blood is the most researched one. At the same time, blood is the most complicated 
of our bodily fluids to analyse, since it on top of EVs contains cells, proteins, lipids and nucleic acids. As 
of yet it has not been possible to develop a method that would isolate pure EVs without any co-isolates. 
Thus, one needs to take into account the molecules that will co-isolate when working with EVs. 
Molecules that tend to co-isolate with blood derived EVs are soluble proteins, protein aggregates, 
lipoproteins and cellular organelles, for instance (Karimi et al. 2018). 
 
Isolating PEVs with a sufficiently good yield free of or lipoproteins or protein-derived contaminants is 
a challenge (Coumans et al. 2017). From a physical point of view, the simplest way of isolating EVs is 
differential centrifugation and indeed a large fraction of EV isolations are preformed this way. 
Differential centrifugation is based on the principle that the natural sedimentation rate of particles is 
accelerated by the centrifugal force. The rate of sedimentation, on the other hand, is dependent on 
the density of the particle to be isolated in relation to the surrounding media. EVs are isolated by 
consecutive centrifugations with increasing centrifugal forces. EVs with higher density are isolated 
when applying lower centrifugal forces whereas EVs with lower density are isolated when applying 
higher centrifugal forces. Applying higher centrifugal forces may result in protein aggregates and EVs 
may also clump together (Coumans et al. 2017). The viscosity and density of plasma makes it a 
challenging media to work with when studying EVS. This fact combined with the lipoproteins in plasma, 
that have the similar density and diameter as EVs, further hampers the isolation of EVs (Théry et al. 
2006, Coumans et al. 2017). A further significant challenge with isolating by means of differential 
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centrifugation, is the fact that it is a highly time-consuming method. By adding filters to the process, 
the size range of the EVs to be isolated can be regulated and in this way differential centrifugation can 
be made more efficient. Unfortunately, EVs are prone to taking damage when filtered if the applied 
force is too high (Coumans et al. 2017).  
 
As implied by its name, density-gradient centrifugation utilises both a density-gradient and 
centrifugation to isolate EVs. Density-gradient is based on particles in a solution, such as EVs, with a 
density higher than the solution, sinking to the bottom of the test tube. Particles less dense than the 
solution, on the other hand, float. As a method of isolation, density-gradient is gentler than filters and 
the result is a contaminant free product (Aatonen et al. 2014). Sucrose or iodixanol are frequently used 
to create the density-gradient. Unlike sucrose iodixanol is isosmotic, inert, nontoxic and self-forming. 
Iodixanol is also less viscous than sucrose (Konoshenko et al. 2018) and the required centrifugation 
time is also shorter. Since EVs remain functional after an isolation by iodixanol, functionality assays 
can be performed on EVs isolated by an iodixanol gradient. Since the osmolarity remains the same, no 
chance in volume occurs during the isolation process, and the density of the EVs remains unchanged. 
There are two types of gradients - the top-down gradient and the bottom-up gradient. The top-down 
gradient is best suited for separating EVs based on their size in diameter (Choi et al. 2011, Willms et 
al. 2016). The bottom-up approach, in the other hand, is best suited when isolating EVs based on the 
buoyant densities (Choi et al. 2011, Willms et al. 2016). The method is challenging and requires 
technical skilfulness, it is time-consuming and there is a risk of severe sample loss. Below is a table 
(Figure 5) that summarises isolation methods that are frequently employed for EV isolation. The 
methods are extensively discussed in the review paper by Konoshenko et al. (Konoshenko et al. 2018). 
 
 
 
Method Isolation principle Pros Cons 
Ultracentrifugation Isolation method based 
in density, size and 
shape. 
Straight forward, 
requirements for technical 
skills negligent, makes large 
sample batches possible, 
high yield 
Time consuming, protein complex 
formation, aggregation, lipoproteins of 
the plasma, high centrifugal velocities 
may damage EVs 
Densitygradient 
ultracentrifugation 
Isolation method based 
on density 
Gentle, results in a pure 
product, functional vesicles 
Technically challenging, laborious, time 
consuming, low yield 
Size exclusion 
chromatography 
Isolation method based 
on differences in size 
Straight forward, gentle, 
fast, pure product 
High probability for lipoprotein 
contamination, small sample volume 
Precipitation with 
polyethylene glycol 
Isolation method based 
on solubility 
Straight forward, makes 
large sample batches 
possible, does not harm EVs 
Contamination sensitivity, time 
consuming, demanding  
Exoeasy Isolation method based 
on affinity 
Fast, makes large sample 
batches possible, does not 
harm EVs 
Lipoprotein contamination, great 
albumin amounts 
Figure 5 Widely used methods for isolating EVs. Adapted from Konoshenko et al. 2018 
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2. Aim of the project 
 
The aim of the project was to investigate the BDNF content in PEVs and further to find out if the means 
of platelet activation has an effect on the BDNF concentration in PEV samples. We were also interested 
in finding the PEV subpopulations carrying BDNF and whether the BDNF concentration varied between 
the different subgroups. For this purpose, a density-gradient system was set up in the laboratory, 
during the project, to isolate PEVs. 
 
3. Materials and methods 
3.1 Isolation of platelets. 
 
The blood used for this research was drawn from healthy volunteers who had given their informed 
consent according to the declaration of Helsinki. The platelet concentrates (PC) were ordered from 
The Finnish Red Cross Blood Service. The PC are produced by the so-called buffy coat method. The first 
step in this process is to centrifuge the whole blood that has been treated with an anticoagulant. By 
doing so the plasma (55%), the erythrocytes (45%) and the buffy coat (< 1%) are separated (Figure 6). 
The buffy coat includes the platelets and the leucocytes. Following the initial centrifugation, the 
leucocytes are carefully filtered out. The PC is produced the same day by pooling the PC of four 
anonymous donors. Finally, a solution, pH 7.2, consisting of sodium citrate, sodium acetate, sodium 
chloride, magnesium chloride and potassium chloride, is added to the PC. 
 
 
Figure 6 A test tube showing the result of the buffy coat method. 
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The platelets were isolated immediately upon arrival according to a protocol developed in the lab 
(Figure 7, Aatonen et al. 2014). 13 ml of the PC was poured into a 15 ml Falcon tube containing 100 ng 
ml-1 prostaglandin E1 (PGE1, Sigma-Aldrich, St. Louis, the USA) and 1/6 v/v acid-citrate-dextrose buffer 
(ACD; 39 mM citric acid, 75 mM sodium citrate, 135 mM d-glucose, pH 4.5) which had been warmed 
to room temperature (RT). The sample was then centrifuged 900 ´ g for 15 minutes RT in a swing out 
rotor without applying brake in an Eppendorf 5702 R table centrifuge (Eppendorf, Hamburg, Germany). 
The resulting platelet pellet was resuspended thoroughly, yet carefully in a Ca2+ free Tyrode-Hepes 
buffer (137 mM NaCl, 0.3 mM NaH2PO4, 3.5 mM Hepes, 5.5 mM d-glucose, pH 7.35) following an 
addition of 100 ng ml-1 PGE1, to keep the platelets from activating in advance. The platelet count was 
measured with a blood cell analyser (Beckman Coulter T-540, Brea, the USA) and a sample was 
collected. Finally, the platelets were isolated from the suspension by size exclusion chromatography in 
the presence of PGE1 (SEC). The CL B2 sepharose (GE Healthcare, Buckinghamshire, the UK) was 
balanced by washing it three times with Ca2+ free Tyrode-Hepes buffer. 10 ml of the sepharose was 
the packed into a 15 ml Telos column (Kinesis Inc., Berlin Township, the USA). 1 ml of the platelet 
suspension was loaded into the column and eluted with Ca2+ free Tyrode-Hepes buffer. 3-4 ml of the 
eluate was collected during the concentration peak. 
 
 
Figure 7 Flow chart displaying the process of platelet isolation from PC. The sample was first pelleted by 
centrifugation. The pellet was then resuspended in 1 ml of Ca2+-free Tyrode-Hepes buffer and finally the 
platelets were isolated by gel-filtration. 
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3.2 Activation of platelets 
 
The platelet count of the eluate was re-measured with the blood cell analyser and the platelet 
concentration was adjusted to 250´106 platelets ml-1. This platelet concentration was chosen, since it 
had previously been shown to be optimal when activating platelets for EV secretion (Aatonen et al. 
2014).  
 
Platelets secrete PEVs as a response to strong agonists or following a peak in the intracellular calcium 
concentration (Siljander et al. 1996). Based on previous observations (Aatonen et al. 2014) it was 
hypothesized that BDNF would be found in the so call exosome fraction following a co-stimulation by 
thrombin and collagen (TC co-stimulation). A TC co-stimulation was performed by pipetting 1 U ml-1 of 
thrombin and 5 µg ml-1 of collagen on the wall of an Eppendorf tube prior to adding the platelet 
suspension. The rise in the intracellular calcium concentration was mimicked by pipetting 10 µM of 
Ca2+ ionophore to the wall of an Eppendorf tube prior to the addition of the platelet suspension. In 
addition to TC and Ca2+ ionophore 1 mM MgCl2, 2mM CaCl2 and 3 mM KCl2 were added to all of the 
tubes. These ions are added in order to support the activation cascade. The control sample was a 
platelet suspension sample that was left unactivated, yet otherwise treated exactly as the activated 
samples. The samples were incubated for 30 minutes at 37 °C without mixing. Finally, 50 µl of the 
activated platelet sample was extracted for staining prior to analysis by flow cytometry. The rest of the 
sample was used for isolation PEVs. 
 
Following activation, the activated platelet samples for flow cytometry were stained for 15 minutes at 
37 °C without mixing. As instructed be the manufacturer, 50 µl of the platelet sample was stained with 
20 µl of the appropriate fluorescent antibody. Following the incubation, 450 µl of Tyrode-Hepes buffer 
was added to the tubes in order to stop the reaction by dilution. For this part of the project, we used 
the fluorescent monoclonal antibody mouse anti-human CD62P (clone AK-4, BD Biosciences, USA) 
conjugated with R-phycoerythrin (PE) as well as the mouse IgG1 κ isotype control (clone MOPC-21, BD 
Biosciences) conjugated with PE. The other antibody that we used was the monoclonal antibody 
mouse anti-human CD41a (clone HIP8, BD Biosciences, Franklin Lakes, The USA) conjugated with 
fluorescein isothiocyanate (FITC) and the mouse IgG1 κ isotype control (clone MOPC-21, BD 
Biosciences, Franklin Lakes, The USA) conjugated with FITC.  
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3.3 Isolation of PEVs 
 
Following the activation of platelets, the platelets and other cell fragments were removed from the 
platelet suspension by three consecutive centrifugations. The first centrifugation was 5000´g, 5 
minutes, RT (Mikro 200R, Andreas Hettich GmbH & Co. Tuttlingen, Germany). In order to make the 
pellet firmer the suspension was the immediately centrifuged again at 11 000 ´g, 1 minute, RT (CM-
50 centrifuge, Elmi Ltd. Riga, Latvia). The supernatant was transferred to a new tube and centrifuged 
at 2 500´g, 15 minutes, RT (Mikro 200R). To make sure that the supernatant was free from platelet 
contamination, a sample was analysed with the blood cell analyser. The final supernatant was then 
transferred into a new tube and stored at -80 °C. Before freezing the supernatant, however, a sample 
of 100 µl was taken and stored at -20 °C. This sample was used for the ELISA analysis.  
 
3.4 Platelet and EV flow cytometry 
 
The platelet activation was analysed by a second-generation flow cytometer, ApoGee A50 Microflow, 
capable of EV detection (Apogee flow systems, Hempstead, the UK). Platelet optimised settings were 
employed for the analysis. The device contains two lasers. The 405 nm laser measures scatter and the 
488 nm laser measures fluorescence. The platelet gates were set for small angle light scatter (SALS) 
and large angel light scatter (LALS) detectors. The voltage for SALS was set to 280 V and for LALS it was 
set for 488 V. We also measured with detectors for 488-green and 488-orange. The voltage for these 
was set for 500 V and 788 V correspondingly. The gain value was set for 1 and the background was 
kept below 0.5. The threshold for SALS was set for 14 and 33 for LALS. Silica beads, with a refractive 
index similar to that of biological particles and a size between 110 nm and 1 300 nm, were used to the 
asses the performance of the machinery. For each measurement, 150 µl of the previously activated 
samples was analysed. Each measurement lasted for 120 seconds, the flow speed was 4.51 µl min-1 
and the machinery was meticulously rinsed following each measurement.  
 
3.5 Density-gradient 
 
A 60% (w/v) iodixanol (OptiPrepTM, Sigma Aldrich, Missouri, the USA) in sterile water. The density of 
60% (w/v) iodixanol is 1.32 g ml-1. According to the manufacturer this density-gradient is well suited 
for isolating cells, cell organelles, viruses and proteins. The method was optimized using platelet free 
plasma (PFP) as we did not have instructions based on previous experiments to go by. The PFP was 
produced from the same PRP as the EV-rich supernatant was isolated (Figure 8). The PFP was then 
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purified by density-gradient centrifugation. Western blot was used to confirm that we had successfully 
isolated particles expressing EV typical markes CD63 and CD9 (Figure 20 and 21) and that the method 
was suited for PEV isolation. 
 
 
 
Figure 8 Flowchart describing how the platelet free plasma was produced for the project 
 
  29 
3.5.1 Applying the density-gradient method 
 
A discontinuous 40%-22% iodixanol gradient was pipetted into 13 
ml centrifugation tubes (Ultra-ClearTM, Beckman Coulter, 
Pasadena, USA) (Figure 9). Each fraction in the gradient was one 
ml, except for the 40% fraction at the bottom of the tube which 
was three ml. The density of the fractions was confirmed by 
densitometry. Thus, the density of the fraction on the bottom of 
the tube was 40% and the confirmed density was 1.215 g ml-1. 
The OptiPrepTMTM concentration of following fractions was 35% 
-22% and the corresponding densities were between 1.190 g ml-
1 and 1.112 g ml-1. Hepes-buffer (10 mM Hepes -140 mM NaCL, 
pH 7.4) was used as diluting agent for the OptiPrepTMTM. As we 
were interested in isolating EVs based on their density, a bottom-up 
gradient was pipetted. The bottom fraction was created by pipetting 
one ml of the sample to two ml of undiluted OptiPrepTM. The following 
one ml fractions were then pipetted on top of the bottom one. The tubes were ultracentrifuged at 100 
000´gavg for 16 hours at +4 °C. (SW40Ti rotor, Beckmann Coulter, Pasadena, USA). The fractions were 
collected, top to bottom, the following day and diluted 1:20 in Hepes buffer. The fractions were then 
ultracentrifuged at 100 000´g for two hours at +4 °C (Ti 50.2 rotor, Beckmann Coulter, Pasadena, USA). 
Following this final centrifugation, the pellets were resuspended in 200 µl Hepes buffer and stored at 
-80°C until analysis.  
 
3.6 Determining the size distribution and concentration of the EV populations 
 
Small particles in liquid, including EVs, can be directly observed and analysed in real-time with 
nanoparticle tracking analysis (NTA). The investigated particles are visualized by light scatter using light 
microscopy. A recording is made of the measurement and the NTA software tracks the Brownian 
movement of each individual particle and calculates the sample specific size distribution and 
concentration based on this. 
 
For the size and concentration determination of the PEV we used an NTA device (LM14C, Nanosight, 
Malvern Instrument, Salisbury, the UK) equipped with a scientific complementary metal-oxide-
semiconductor (sCMOS) camera and a 405 nm blue diode laser (Hamamatsu Photonics K.K., 
Figure 9 A photo of the iodixanol 
gradient used in the project. A 
bottom-up gradient was chosen, 
since we were interested in 
separating PEVs based on their 
density. 
Figure 9 A photo of the iodixanol 
gradi nt used in the pr ject. A 
bottom-up grad en  was chosen, 
since we were interested in 
separating PEVs based on their 
density. 
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Hamamatsu City, Japan). When necessary the device was calibrated with 0.2 mm Fluoresbrite 
Multifluorescent Microspheres (Polyscience, Warrington; the USA). The results were analysed with the 
NTA 3.0 operating system. The analysis settings were expert, back-ground-extraction, auto blur, and 
autominimum track length on. The smallest expected particle was set for 50 nm as the cut-off value 
for EV measurements by NTA is 70 nm. Particle detections below 70 nm are not reliable. The samples 
were injected manually with a one ml Terumo syringe (Terumo Corporation, Shibuya, Tokyo, Japan) 
such that the sample chamber became full. The measurements were performed as 60 second 
triplicates per sample at a measuring temperature of 25 °C. The samples were diluted in Hepes buffer 
such that the sample concentration was approximately 40-100 particles frame-1. This particle amount 
corresponds to 108-109 particles ml-1. 
 
3.7 SDS-Page and Western blot 
 
Before the ELISA analysis, the PEV samples were probed for BDNF and EV markers by SDS-Page and 
Western blot. The positive and negative BDNF controls were a kind gift from Eero Castrén’s group 
(University of Helsinki). The positive control was a brain lysate of a wild type mouse and the negative 
control was the brain lysate of a BDNF- knockout mouse i.e. the BDNF coding gene had been silenced 
in the knockout mouse. The PC sample and the SEC-purified platelet samples were also considered as 
positive controls. The protein concentration of the mouse brain lysates used as controls was 
determined by a commercial kit (DC Protein Assay, BioRad, Hercules, the USA) and measured with a 
Multiscan EX spectrometer (MTX Labsystems Inc., Bradenton, the USA). The protein concentration of 
the PEVs was not determined at this point, since the samples had not been purified and therefore, it 
was impossible to know what part of the protein concentration was constituted by PEVs and what was 
something else. As such the protein concentration would not have been useful information for 
determining the amount of sample needed for the SDS-Page analysis. Since BDNF had not previously 
been probed from in PEV samples we decided to add as much sample on to the gel as possible. The 
proteins in the samples were separated on a self-cast gel that depending on the sample type was 10%-
15%. Consequently 50 µl of the PEV rich supernatant per well and 50 µg of the control samples per 
well was pipetted into the wells. When analysing the samples purified by density-gradient 
centrifugation 50 µl was also the amount pipetted per well. The samples preceding, and following SEC 
were presumed to be a lot more protein rich and thus only 20 µl well-1 was loaded onto the gel. The 
samples were run at 80 V-120 V until the sample front was close to the lower edge of the running gel.  
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Following the gel electrophoresis, the proteins were transferred onto a methanol activated PVDF 
membrane (EMD Millipore Corporation, Burlington, the USA) by electrophoresis. The so-called wet 
blot protocol was used in this project and the proteins were transferred for one hour at a constant 
voltage of 100 V. The membranes were then incubated for at least two hours in 5% milk-TBST-buffer 
(50 mM Tris, 150 mM NaCl, 0.01% Tween). Following the blocking the PVDF membranes were 
incubated with the primary antibody for a minimum of two hours. The membranes were then washed 
three times for 15 minutes in TBS-T buffer. In this project the membranes were probed with anti-BDNF 
(1:1500 dilution) (Clone 3C11, Icosagen, Tartu, Estonia), anti-CD-41(1:2000 dilution) (Clone SZ22, 
Beckman Coulter, Brea, the USA) and anti-CD9 (1:500 dilution) (Clone M-L13, Beckton Dickinson, NJ, 
the USA) and anti-CD63 (1:500 dilution) (Clone H5C6, Beckton Dickinson, Franklin Lakes, the USA). The 
membranes were then washed three times with TBS-T for 15 minutes. Following the washes, the 
membranes were incubated for 45 minutes with the secondary antibody (1:2000 dilution), HRP-
conjugated anti-mouse IG (GE Healthcare, Chicago, the USA). Finally, the membranes were again 
washed three times for 15 minutes and they were then incubated for 5 minutes in Clarity Western ECL 
substrate (Bio-Rad Laboratories, Hercules, the USA). The membranes were developed on Amersham 
Hyperfilm ECM film (GE Healthcare Lifesciences, Little Chaifont, the UK) or detected by luminescense 
by a Las3000 LITE luminescent image analyser (Fuji, Valhalla, the USA). 
 
3.8 ELISA analysis 
 
For the determining of the BDNF concentration by enzyme-linked immunosorbent assay (ELISA) 
instructions by Roche from 2006 were employed. The method was routinely used in the laboratory. 
Unless otherwise stated, all of the reagents in this part were by Roche (Hoffman-La Roche, Basel, 
Switzerland). We used the so-called indirect ELISA method, since it is very well suited for determining 
the total concentration of an antibody in a sample. This is a two-step ELISA consisting of two binding 
processes. The primary anti-body is first incubated with the antigen and this is followed by an 
incubation with an enzyme conjugated secondary antibody. 
 
In the first part of this analysis 200 µl of the primary anti-body, anti-BDNF #1, diluted 1:4000 in 
carbonate buffer, pH 9.7 (50 mM NaHCO3, 50 mM Na2CO3) was pipetted onto a 96-well plate. The 
plate was incubated overnight on a shaker at +4 °C. The following day the carbonate buffer was 
discarded. Now 300 µl of Hanks buffer pH 7.4 (125 mM NaCl, 5mM KCl,1,2 mM NaH2PO4, 1 mM CaCl2, 
1,2 mM MgCl2, 1 μM ZnCl2, 10 mM glucose, 25 mM Hepes, 0,25% BSA, pH adjusted with NaOH) to 
which 2% BSA and 0.1% v/v had been added, was pipetted into the wells. The plate was again 
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incubated over night at +4 °C on a shaker. The next day the samples were pipetted onto the plate. The 
samples had been diluted in Hanks buffer in such a way that the same amount of sample was used as 
in SDS-Page and the final volume was 170 µl. 30 µl of peroxidase conjugated (POD) anti-body #9 (anti-
mouse) was pipetted onto the plate as well. This secondary antibody had been diluted 1:1900 in Hanks 
buffer with added 6.66% BSA and 0.66% v/v Triton x-100 (Sigma Aldrich, St Louis, the USA). Thus, the 
final 200 µl sample contained 1% BSA, 0.1% v/v Triton x-100 and 16 mU BDNF-POD. This was followed 
by a third overnight incubation at +4 °C on a shaker. The following day the buffer was discarded, and 
the 96-well plate was washed three times with 300 µl well-1 of PBS-T buffer (137 mM NaCl, 2.7 M KCl, 
10 M Na2HPO4, 1.8 M KH2PO4, 0.1% Tween-20). The protein concentration in the standards were 0, 4, 
8, 16,24, 32, 48, 64, 96 and 138 pg ml-1. For the detection 200 µl of POD substrate was added into each 
well. The samples were incubated in the dark for 20 minutes at room temperature. The reaction was 
then stopped by adding 50 µl of 1 M H2SO4 into each well. By adding the sulphuric acid, the pH in the 
sample changes so drastically it renders the enzyme inactive and hence the reaction is forced to a stop. 
The samples are then analysed by the ELISA software (Varioscan® Flash, Thermo Fischer, Waltham, the 
USA), and in Excel.  
 
3.9 Protein concentration measurement 
 
The protein concentration of both the PEV samples and for the BDNF standards was determined by 
Bio-Rad’s DC protein assay kit (Bio-Rad, Ca, the USA). The standards for the measurement (2.0 mg ml-
1, 1.5 mg ml-1, 1.0 mg ml-1, 0.5 mg ml-1, 0.2 mg ml-1) were produced by diluting an albumin standard 
(Bio-Rad) in the same buffer as the one the samples were in. According to the manufacturer’s 
instructions 5 µl of both standard and sample was pipetted onto a dry and clean microtiter plate 
(Greiner Bio One, Austria). Samples and standards were pipetted as triplicates. According to the 
instructions 25 µl of reagent A and 200 µl of reagent B was pipetted into se wells. The samples were 
then gently mixed to avoid creating bubbles. Following a 15-minute incubation at room temperature 
the absorbance was measured at wavelength 560 nm by a spectrophotometer (LabSystems Multiscan 
EX, Thermo Fischer, MA, the USA). The results were then analysed by Excel.  
 
3.10  Statistical analysis 
The results were analysed with the GraphPad Prism software (GraphPad Software Inc., version 8.3.0). 
The statistical significance between two groups were analysed by a paired student’s t-test. A p-value 
of £ 0.05 was considered statistically significant. 
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4. Results 
4.1 Flow cytometry  
In order to assess the success of the platelet activation we analysed the samples by flow cytometry. We had 
previously stained the samples of activated platelets and these samples were now analysed with a second-
generation Apogee A50 Micro Flow Cytometer.  
 
Sample A (Figure 10) is the unstimulated control sample stained with anti-CD41. The analysis for CD41 was 
done in order to ensure that the particles were indeed platelet derived and that they had remained inactive 
during the isolation process. Sample B (Figure) is the sample derived from Ca2+ionofore stimulated platelets 
(Figure 10). The ApoGee data shows that in the stimulated sample 91.51% of the particles were positive for 
CD62P i.e. activated. Sample C (Figure 10) is the sample derived from TC co-stimulated platelets. When 
analysing these samples, the data showed that 90.1% of the particles in the stimulated samples were CD62P 
positive i.e. activated. 
 
 
Figure 10 Platelet analysis by flow cytometry with the Apogee A50 Micro Flow Cytometer. The presented 
dot plots are A) the control sample stained with anti-CD41 B) platelet sample activated by Ca2ionofore 
stained with anti-CD62P C) platelet sample activated by TC co-stimulation and stained with CD62P 
 
 
 
 
 
 
 
LALS 
SALS 
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4.2 NTA analysis  
Next, we wanted to compare the yields of PEVs after the different stimulations. The size distribution 
and concentration of the particles produced by TC co-stimulation and Ca2+ionofore stimulation was 
analysed by NTA after total removal of platelet remnants. The NTA does not discriminate between 
particles, it detects all of them regardless if they are EVs, lipoproteins or protein aggregates. As such, 
we refer to particles, when discussing NTA results and not EVs, although lipoproteins and aggregates 
are less of a problem when we use isolated platelets rather than plasma. The samples were diluted 
such that 40-100 particles/ frame were obtained. This particle concentration approximately 
corresponds to 5´108 particles ml-1 which is considered the optimal concentration of particles for 
analysis. 
 
Based on the NTA analysis (figure 11) the particle amount in the sample derived from the TC co-
stimulation increased 1.6 in relation to the control (p = 0.037). The control sample contained particles 
from the inactivated sample. The particle amount in the Ca2+ co-stimulation derived particles increased 
significantly more – 14.8 times when compared to the control sample (p = 0.032). The results are a 
mean of three independent measurements and each measurement was carried out as triplicates.  
 
 
Figure 11 Particle amount in the samples from the platelet activation by TC co-stimulation and Ca2+ionofore 
measured by NTA. The control sample is from the unactivated sample. The particle amount in the samples 
derived from the TC co-stimulation increased 1.6 times in relation to the control. The particle amount in the 
samples derived from the Ca2+ionofore stimulation, however, increased 14.8 times in relation to the control. 
The samples were measured as triplicates and the results are the mean ±SEM/SD of three independent 
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measurements. The SD for the control sample, the TC co-stimulation sample and the Ca2+ionofore sample 
was 1.27, 2.9 and 7.5 respectively. 
 
 
The precentral size distribution of the particles in the samples was also analysed by NTA (Figure 12). 
Three independent measurements were performed, and each measurement was repeated three 
times. The majority i.e. 61.5% of the particles in all three sample types were 100-250 nm in diameter. 
Stimulation by Ca2+ionofore produced twice as many particles with a diameter less than 100 nm when 
compared to the control sample (p = 0.027) and three times as many as when compared to TC co-
stimulation (p = 0.003). This corresponded well to previous results from the laboratory (Aatonen et al. 
2014). Of the particles derived from the Ca2+ionofore stimulation, approximately 14% had a diameter 
between 250 nm and 500 nm. The particle amount in this size class was larger in both the control 
sample and the particles derived from the TC co-stimulation, 24.42% and 29.32% correspondingly. In 
all three sample types a very small amount of the particles represented a size class larger than this.  
 
 
Figure 12 Percentile size distribution of the particles as analysed by NTA and corresponding statistical 
significance. For all three samples the majority of the particles were within 100-250 nm in diameter. 
Stimulation by Ca2+ionofore produced more particles less than 100 nm in diameter when compared to the 
control and the TC co-stimulation-derived particles. The samples were measured as triplicates and the result 
is the mean ±SEM/SD of three independent measurements 
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The yield of the samples purified by density-gradient centrifugation was analysed by NTA (Figure 13). 
When considering the total particle amount, a large loss of sample was observed. When comparing 
the total amount of particles of the uncentrifuged sample to the total particle amount in the sample 
purified by density-gradient centrifugation the yield for the control sample was 11% (SD = 2.1). The 
yield for both the particles derived from the TC co-stimulation and the Ca2+ionofore stimulation was 
17% (SD = 2.7).  
 
 
Figure 13 Comparison of particle concentration pre- and post-density-gradient centrifugation. A substantial 
sample loss was observed. When comparing the total amount of particles of the uncentrifuged sample to 
the total particle amount in the sample purified by density-gradient centrifugation the gain for the control 
sample was 11%. The gain for both the particles derived from the TC co-stimulation and the Ca2+ionofore 
stimulation was 17%. The samples were measured as triplicates and the result is the mean ±SEM/SD of three 
independent measurements. 
 
 
The size distribution of the particles derived from the TC co-stimulation was also analysed by NTA as 
percentile (Figure 14). All collected fractions were analysed and the particle richest fraction was 
expected to be within the density group 1.112 g ml-1-1.142 g ml -1 (Konoshenko et al. 2018). The 
particles with a density of 1.112 g ml-1 had a mean size of 140 nm in diameter. These particles 
dominated the groups <100 nm and 100-250 nm. Particles in the density group 1.132 g ml-1 had a mean 
size of 256 nm in diameter and they were plentiful in the groups 100-250 nm and 250-500 nm. Particles 
with a density of 1.142 g ml-1 had a mean size of 432 nm in diameter. Particles with a density of 1.153 
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g ml-1 had a mean size of 443.5 nm in diameter. Particles with the density 1.163 g ml-1 had mean size 
of 478.5 nm in diameter. Particles with the density 1.19 g ml-1 had mean size of 580 nm. Finally, 
particles with a density of 1.215 had a mean size of 609 nm in diameter. This data fits previous data 
well (Aatonen et al. 2014). 
 
The particles of smaller densities i.e.1.112-1.142 g ml-1 were the most abundant ones in the particles 
with a mean size between 250 and 500 nm in diameter. They were less frequent in the group with a 
particle size of 500-750 nm in diameter, and they were non-existent in the group with particles with a 
diameter between 750 and 1000 nm.  
 
 
Figure 14 Density distribution and corresponding size of the particles derived from the TC co-stimulation 
of platelets. The density distribution of the particles within the different size groups was analysed by 
NTA. Particles with smaller densities dominated the groups of smaller diameters while particles of 
larger densities dominated the groups of bigger diameters.  
 
 
The particles from the Ca2+ionofore stimulation were also analysed by NTA (Figure 15). The results 
were quite similar as for the particles from the TC co-stimulated samples. However, it seems that the 
number of particles with a diameter less than 250 nm were somewhat more frequent in particles from 
the Ca2+ionofore stimulation. A variation was also discovered regarding the mean size distribution of 
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the particles. The mean diameter of particles with a density of 1.112 g ml-1 was 163.3 nm. The mean 
diameter of particles with a density of 1.132 g ml-1 was 242.5 nm. For particles with a density of 1.142 
g ml-1 had a mean size of 345 nm in diameter. For particles with a density of 1.153 g ml-1 had a mean 
size of 440 nm in diameter. Particles with a density of 1.163 g ml-1 had mean diameter of 454 nm. The 
mean diameter of particles with a density of 1.19 was 539.8 nm. Finally, the particles with a density of 
1.215 g ml-1 had a mean diameter of 541 nm. Statistically, however, this variation was not significant. 
 
 
Figure 15  Density distribution and corresponding size of the particles derived from the stimulation by 
Ca2+ionofore. The density distribution of the particles within the different size groups were analysed 
by NTA. The density to diameter distribution appeared fairly similar to that of the TC co-stimulation. As 
a result of the Ca2+ionofore stimulation, however, the number of particles of smaller density was 
somewhat larger, effect of the unselective nature of the Ca2+ionofore stimuli. 
 
The mean size distribution, of the samples derived from both the TC co-stimulus and the Ca2+ionofore 
stimulus, is displayed in the figure below (Figure 16). The variation in size depending on applied 
stimulus was not significant statistically. In all of the density groups, except for the particles with a 
density of 1.112 g ml-1, the particles derived from the TC co-stimulus had the larger mean diameter 
compared to particles derived from stimulus by Ca2+ionofore. 
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Figure 16 Comparison of the mean size distribution of the analysed particles. The applied stimulus on 
the density to diameter distribution does not appear statistically significant. Except for the particles 
with a density of 1.112 g ml-1, the particles derived from the TC co-stimulus had the largest mean 
diameter. 
 
4.3 Characterization of PEV by immunochemical methods 
 
In this project the Western blot method was used in order to confirm a) that the isolated particles 
express EV typical cell-surface proteins and b) the expression of BDNF in the isolated particles. The 
expression of BDNF was further investigated by ELISA in order to gain both qualitative and quantitative 
data regarding the BDNF concentration in the particles.  
 
4.3.1 Probing for the presence of EV surface markers on PEVs induced by TC/Ca2+ionofore 
activation 
 
The presence of EV typical cell-surface proteins CD9 and CD63 in the PEV samples was investigated by 
Western blot. CD9 is a cell-surface glycoprotein that is a member of the tetraspanin family. It binds to 
integrins and modulates cell adhesion and cell migration (Chen et al. 1999). It also triggers platelet 
activation and aggregation. CD63 is also a member of the tetraspanin family that binds to integrins. It 
also forms complexes with intracellular vesicles and may also function as a marker for platelet 
activation (Cashicar and Hanson 2019). 
 
The PEV samples derived from the TC co-stimulation and purified by density-gradient centrifugation 
showed a strong positive signal for CD9 at approximately 25 kDa (Figure 17). Iodixanol fractions 22% 
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(1.112 g ml-1) and 24% (1.132 g ml-1) showed the strongest signal. Fractions 26%-35% (1.142 g ml-1-
1.190-g ml-1) were also positive, although the signal was not as strong. When probing for CD63, 
iodixanol fractions 22% (1.112 g ml-1) and 24% (1.132 g ml-1) also gave the strongest positive signals 
(Figure 18). Similar to CD9, fractions 26%-35% (1.142 g ml-1-1.190-g ml-1) also gave a weaker, yet 
positive signal (figure 18).  
 
 
Figure 17 Western blot membrane probed with a CD9 antibody. The analysed sample was a TC co-
stimulation derived PEV sample that was purified by density-gradient centrifugation. Fractions 35—22% 
1.190 g ml-1-1.112 g ml-1) were positive for CD9, whereas fractions 40% (1.215 g ml-1) and 20% (1.092 g ml-
1) were negative. The strongest signal was detected in fractions 22% and 24% The expected molecular 
weight for CD9 is approximately 25 kDa and it is indicated by an arrow. Results are representative of three 
repeats. 
 
 
 
Figure 18  Western blot membrane probed with a CD63 antibody. The analysed sample was a PEV sample 
derived from TC co-stimulation was then purified by density-gradient centrifugation. Fractions 22%-35% 
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were positive for CD63 whereas fractions 40% and 20% were negative. Fractions 24% and 22% gave the 
strongest signal. The expected molecular weight for CD63 is approximately 65 kDa is indicated by an arrow. 
Data is representative of three repeats 
.  
 
Investigating the expression of BDNF in PEVs was a central aim of the project and as such the samples 
derived from the platelet activation were also probed for BDNF by Western blot analysis (Figure 19). 
In the figure the wells are marked with numbers and the corresponding samples are listed in the figure 
legend. The pre and post sec samples (sample 1 and 2) showed a strong positive signal at 11 kDa. There 
was also plenty of unspecific binding. The PEV sample derived from the TC co-stimulation (sample 4) 
was positive. The PEVs derived from the Ca2+ionofore activation (sample 5) were BDNF negative. As 
expected, the platelet samples that were left inactivated during the activation process (sample 6) were 
BDNF negative. This sample can be considered as a negative control. The brain lysate sample from 
mouse that was used as a positive control (sample 9) only gave a very faint signal although we pipetted 
approximately 50 µg of it onto the gel. The same amount of the brain lysate used as a negative control 
was pipetted on to the gel (sample 8) and it appears BDNF negative.  
 
 
Figure 19 Western blot probed for BDNF. The highly positive signals in lane 1 and 2 are platelet samples pre- 
and post- isolation by size exclusion chromatography. The sample in lane 4 is TC co-stimulation-derived 
PEVs. The Ca2+ionofore-derived PEVs in lane 5 were negative as were the unactivated PEV samples in lane 
6. The positive control of mouse brain lysate in lane 9 gave a very faint positive signal visible only with 
overexposure of the gels. The expected molecular weight of BDNF is approximately 11 kDa is indicated by 
an arrow. Results are representative of three repeats. 
 
 
The PEVs purified by density-gradient centrifugation were also probed for BDNF by Western blot 
analysis. Based on the results, BDNF was enriched in fractions 22% and 24%, the latter giving the 
stronger positive signal (Figure 20). These fractions correspond to densities 1.112 g ml-1 and 1.132 g 
ml-1 . The other fractions appeared to be BDNF negative even at longer exposures (data not shown).  
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Figure 20 Western blot probed for BDNF. TC co-stimulation derived PEVs were purified by density-gradient 
centrifugation. Fractions 22% and 24% were positive for BDNF whereas the other fractions appeared to be 
BDNF negative. Results are representative of three repeats. The expected molecular weight of BDNF is 
approximately 11 kDa is indicated by an arrow 
 
4.3.2 ELISA analysis 
Once we had confirmed the presence of BDNF in our PEV samples we proceeded to analysis by ELISA, 
in order to obtain quantitative data. During the project, two ELISA analyses were run. For this first 
analysis we used the same sample volumes of PEVs as we did for the Western blot analysis. We chose 
to use the same samples undiluted since BDNF concentrations in PEVs had not previously been 
determined. In other words, there were no reference amounts available to proceed by. It turned out, 
however, that the samples were too concentrated for the ELISA since it is a more sensitive analysis. 
For the second ELISA (Figure 20) we made a dilution series where every sample was diluted 1/3 from 
the previous one. By doing so we ensured that our absorbance rates were within linear range of our 
BDNF standard curve. 
 
The PEVs resulting from the TC co-stimulation contained the highest amount of BDNF relative to the 
total protein concentration of the samples analysed (Figure 21). Somewhat surprisingly the PEVs 
resulting from the Ca2+ionofore activation also contained some BDNF relative to the total protein 
concentration (Figure 21). The inactivated samples also contained BDNF (Figure 21). However, the 
amount normalised to the total protein concentration was only 33% compared to that of the PEVs 
derived from the TC co-stimulation. The platelet samples that we reused as positive controls also 
contained a lot of BDNF (Figure 21). 
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Figure 21 Figure displaying the BDNF-concentration in the PEV samples when normalized to protein 
concentration. Samples 1-5 are TC co-stimulation-derived PEVs as a dilution series. Samples 6-9 are 
Ca2+ionofore co-stimulation-induced PEVs as dilution series. Both sample types were diluted such that the 
next sample is diluted 1/3 in relation to the previous one. Sample 10 is the unactivated sample, samples 11 
and 12 are platelet samples pre- and post- isolation by size exclusion chromatography. Sample 13 is the 
negative control and sample 14 is the positive control. Data is representative of three measurements. 
 
Further we also wanted to analyse the BDNF concentration in relation to the particle concentration 
measured by NTA (Figure 22). When normalising the BDNF concentration to the particle amount the 
platelet control contained 0,263 pg particle-1. The PEVs from the TC co-stimulation contained 0.46 pg 
particle-1 and the PEVs from the Ca2+ionofore stimulation contained 0.053 pg particle-1. This was 
expected due to the protein poor content of Ca2+ionofore induced EVs as shown by Aatonen et al. 
2014.  
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Figure 22 Analysis of BDNF concentration/particle measured by NTA. In the PEV samples we found that the 
control sample contained 0.263 pg BDNF particle-1 whereas the particles derived from the TC co-stimulation 
contained 0.46 pg particle-1. The CA2+ ionophore stimulation derived particles in the other hand contained 
0.053 pg particle-1. 
 
5. Discussion 
 
To ensure the reliability and reproducibility of EV related research, it is paramount that the analytical 
methods chosen compliment and reinforce each other. Also, to meaningfully claim that the results are 
EV-related and not co-isolate-related, we also need to evaluate the chosen methods critically. In the 
following, I want to address the analytical results of this study and to discuss the obtained results in 
the light of current EV-research. The fact that the obtained results are based on very few repeats (n) 
needs to be taken into consideration and as such conclusions should not be drawn lightly. 
 
5.1 Flow cytometry 
 
In this project, we wanted to investigate the BDNF-content in PEVs and further if the means of 
activation has an effect on the BDNF concentration or if it localizes into certain subpopulations. For 
this purpose, we stimulated the platelets in order for them to secrete PEVs. For the success of the 
project, it was important to know, with certainty, that the analysed PEVs were the result of agonist 
stimulation.  
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Based on the data from the flow cytometry, it is safe to say that the platelets treated with agonists had 
indeed become activated and that they secreted particles. As the control samples had remained largely 
inactive, it is also safe to say that the platelet activation was a result of the agonist treatment and not 
of careless platelet handling, for instance. The flow cytometry also confirmed that we were analysing 
PEVs since the inactivated particles were CD41 positive. 
 
5.2 Immunochemical methods 
 
PEVs derived from platelet activation were analysed by both Western blot and ELISA. By Western blot 
we confirmed the presence of typical EV proteins, such as CD9 and CD63. The expression of the 
platelet- and PEV-specific protein CD41 was confirmed by flow cytometry. The expression of CD9 and 
CD63 was confirmed by Western blot for both TC co-stimulation-derived PEVs and Ca2+ionofore 
stimulation-derived PEVs. The expression of these proteins was also confirmed for the samples purified 
by density-gradient centrifugation. The several bands appearing on the Western blot probed for CD63 
was due to the fact that CD63 has several isoforms i.e. it is not due to unspecific binding for instance. 
It is also worth noting that there, as of yet, does not exist an internal loading control for PEVs. This is 
why we probed for EV typical markers when aiming to verify the presence of PEVs. This is one example 
highlighting the need to verify EV related results from several angels.  
 
As both CD9 and CD63 are members of the tetraspanins superfamily also analysing the PEVs for other 
EV typical markers would have been commendable (Théry 2018). The guidelines for qualitative EV-
research are comprehensively discussed in the Minimal Information for Studies in Extracellular Vesicles 
(MISEV) (Théry et al. 2018). The tumour susceptibility gene 101, also known as TSG101, for instance is 
a cytosolic protein and not a membrane associated one such as CD9 and CD63. Thus, adding it to the 
analysis would have provided more solid proof for claiming that the isolated particles were indeed 
PEVs. Since there, as of yet, is no internal loading control for EVs it is recognised that several EV typical 
markers should always be probed for when analysing EVs immunochemically. ISEV also recommends 
verifying the presence of transmembrane proteins or lipid-bound extracellular proteins and cytosolic 
proteins in EV samples as negative controls (Théry et al. 2018). Since several comprehensive studies in 
PEV proteins had previously been carried out in the laboratory of Siljander it was not viewed as 
necessary for this particular study to perform a more extensive verification, however. Also, since we 
were interested in seeing whether the BDNF is soluble or EV-cargo we only performed a very 
rudimentary Western blot without quantification of protein bands and Ponceau S staining. 
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For a more thorough analysis it would also have been beneficial to analyse the samples for the plasma 
protein apolipoprotein B (Apo B). ApoB is the most common marker for chylomicrons - low density 
lipoprotein and very low-density lipoproteins. ApoB often co-isolates with the EVs of plasma and serum 
and it is regarded as one of the best negative controls when investigating PEVs (Théry et al. 2018). 
Based on possible ApoB-content we would have been able to assess the purity of our samples and thus 
the reliability of our results. Density-gradient ultracentrifugation is one of the methods by which the 
EV community hopes to get samples free from contaminants. It is, however, a recognized problem that 
this method has a very low yield and that soluble proteins remain as challenging contaminants (Karimi 
et al. 2018).  
 
The main objective of the project was the BDNF cargo of PEVs. When probing for BDNF by Western 
blot the weakness of positive control i.e. the brain lysate of a knock-out mouse became a challenge. 
We only managed to get a signal from the positive control when probing for BDNF in PEVs purified by 
density-gradient ultracentrifugation (Fig. 23). This weakness may have been caused by aging of the 
sample or storage related issues. As it was known that platelets contain BDNF the pre- and post-sec 
samples were also expected to contain plenty of BDNF (Fujimura 2002). This was indeed confirmed by 
Western blot analysis. In other words, this positive control worked. The several protein bands 
appearing on the blot are likely to be isoforms of BDNF. The PEVs derived from the TC co-stimulation 
were positive for BDNF as well according to the Western blot analysis. This result was in line with 
earlier publications (Fujimura et al. 2002, Aatonen et al. 2014). The fact that the signal was significantly 
weaker than the signal from the pre- and post-sec is unsurprising. After all we did not aim on loading 
the same amounts of protein on to the gel, since we did not know what the EV to total protein 
concentration in the samples was. Also, from previous research we knew that the distribution of BDNF 
between the platelet cytoplasm and the alfa-granule is 70:30 (Fujimura et al 2002, Tamura et al. 2011) 
and further that the BDNF within the alfa-particles is secreted upon activation and the rest of the BDNF 
remains within the cytoplasm of the platelet (Tamura et al. 2011). Thus, the amount of BDNF within 
the platelet is likely to be significantly larger than that of the PEV (cytosolic). Based on the Western 
blot the PEVs derived from the Ca2+ionophore stimulation appeared to be void of BDNF-content. 
However, based on both the results in this project and results from previous studies (Aatonen et al. 
2014) it is known that Ca2+ionophore stimulation of platelets produces a large population on PEVs that 
are relatively protein poor and thus this result alone was not enough in order to call these PEVs BDNF-
negative. 
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Indeed, the ELISA analysis, which is more sensitive than Western blot, confirmed that the 
Ca2+ionophore stimulation derived PEVs did contain BDNF. When analysing the results however, it 
became clear that even though the BDNF concentration in relation to the total protein concentration 
appeared promising, the BDNF concentration per particle was in fact miniscule. Supporting the 
Western blot finding the BDNF concentration of the Ca2+ionophore stimulation derived PEVs was 
roughly 1/5 compared to that of the TC co-stimulation derived PEVs. As the BDNF concentration was 
normalised to protein content the PEVs derived from the TC co-stimulation were richer in BDNF than 
the other samples, including the platelets. Again, it must be kept in mind that we did not load equal 
amounts of protein for the ELISA analysis. For the first ELISA analysis we loaded equal volumes of the 
samples as we had loaded for the Western blots and for the second, we made a dilution series of our 
samples. Ideally, there would have been more time to optimize the method and the subsequent results 
would then be more than indicative as is the case now.  
 
5.3 Determining of BDNF location in PEVs 
 
By isolating the PEVs by differential centrifugation we had hoped to define in which PEV subfraction 
the BDNF rich PEVs were localized. Unfortunately, most likely due to sample loss, the fractions we 
analysed by ELISA all appeared to be BDNF negative (data not shown). Fortunately, we were able to 
confirm by Western blot that there were in fact BDNF positive fractions namely, fractions 22% and 
24% of the TC co-stimulated samples. In other words, we know that the method works and that BDNF 
does localise in the subfractions where exosomes are expected to localise (Onódi et al. 2018). The 
samples analysed by Western blot which indicated that fractions 22% and 24% were BDNF positive and 
the ELISA which indicated otherwise where not the result of the same PEV isolation. In other words, it 
is quite possible that a new analysis would provide us with another kind of result.  
 
The PEV-yield of the density-gradient centrifugation (17%) was not great, although within the limits 
provided by literature. Based on published literature the gain for EVs isolated by density-gradient 
centrifugation is between 10% and 50% (Coumans et al. 2017). The sample loss was probably, at least 
in part, due to the final step of the protocol where the fractions from the density-gradient 
centrifugation were collected, diluted 1:20 in Hepes buffer, ultracentrifugation, and resuspended in 
Hepes buffer in order to get rid of the iodixanol. By using a larger or more concentrated sample amount 
in the beginning of the density-gradient centrifugation, the yield is most likely to be improved. Also, 
obviously, having more time, to optimize the method and improve the technical skills of the person 
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performing the experiment, would minimize the sample loss and make the whole process more 
efficient. 
 
5.4 Determining the size distribution of particles derived from activated platelets 
 
When analysing the properties of the particles derived from the activated platelets by NTA we saw 
that both the size-distribution and the particle concentration, more or less, corresponded to the results 
acquired in the lab before (Aatonen et al. 2014). The particle concentration did not increase 
dramatically when activating platelets by TC co-stimulation as compared to the control sample. The 
protein content, however, was higher in the particles activated by TC co-stimulation than in the control 
sample. The particles derived from the platelets that were activated by Ca2+ionophore, on the other, 
were greater in number as compared to both the control sample and the particles derived from the TC 
co-stimulation. Meanwhile, they were quite protein-poor. This tells us that platelets pack proteins into 
PEV based on the signal they receive. Ca2+ionofore being a very general platelet activating agonist 
mainly produces vesiculation, whereas TC co-stimulation produces a selective packing of proteins into 
EVs as  
 
Based on combined results from both Western blot, ELISA and NTA there appears to be enrichment of 
BDNF in the 22% and 24% density-gradient fractions. This corresponds to particles that have a density 
of 1.112 g ml-1 and 1.132 g ml-1 correspondingly. For particles derived from the TC co-stimulation these 
densities imply that the particles are less than 500 nm in diameter. The majority of the particles with 
a density of 1.112 g ml-1 correspond to particles with a diameter of 100-250 nm. This was also the size 
group with the largest particle concentration. The particles with a density of 1.132 g ml-1 were divided 
fairly equally between the groups with a diameter of 100-250nm and 250-500nm. Unfortunately, we 
do not have data for the density centrifuged samples of Ca2+iionofore stimulation derived particles. 
This is most likely caused by the combination of sample loss and the protein poor nature of these 
particles.  
 
5.5 Conclusions 
 
What makes PEVs, and EVs in general, such a fascinating field of study is the fact that they participate 
in such a broad array of physiological and pathophysiological processes and these processes can be 
contradictory, from time to time. As such, intercellular communication is, in part, based on the 
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formation of a functionally diverse population of EVs that are produced by the cells for a specific 
function. 
 
We set out to confirm our previous observations by mass spectrometry that BDNF is secreted into 
PEVs. We also wanted to investigate what kind of effect the means of activation had on the BDNF-
content and the localization of BDNF into the PEV subpopulations. The data presented in this thesis 
affirms the active secretion of BDNF into PEVs derived from TC co-stimulation. This implies that BDNF 
is secreted into PEVs as a thrombogenic response, for instance in coronary heart disease (Amadio et 
a. 2019). Lower concentrations of peripheral BDNF concentrations are associated with bigger clots and 
greater fibrin clot strength and higher fibrin fiber complexity, when compared to healthy control 
subjects (Amadio et al. 2019). As such, BDNF may be of potential both as a biomarker and as a 
therapeutic agent for patients suffering from coronary heart disease. The fact that cargo is selectively 
and specifically packed into EVs is supported by published results as reviewed extensively, for instance 
by, Anand et al. and Margolis and Sadovsky (Anand et al. 2019, Margolis and Sadovsky 2019). As a 
further endeavour, it would be interesting to look deeper into how other platelet agonists might affect 
the BDNF content. It would be interesting to analyse and concentrate the supernatant to measure the 
amount, if any, of BDNF in the supernatant. 
 
During the project we worked on trying to develop a method for isolating contaminant free PEVs. We 
also wanted to isolate PEVs based on their density. The method proved to be laborious and time-
consuming. A further downside was the low gain which, at least in part, was due to sample loss. The 
purpose of isolating PEVs based on their density was to see whether platelet-derived BDNF localises in 
specific PEV subgroups or not. Based on our results BDNF seems to localise in platelets with a density 
of 1.112 g ml-1 and 1.1132 g ml-1. In other words, BDNF seems to localise in the so-called exosome 
fraction. When verified, this information is useful when, for example, developing BDNF related 
therapeutic drug delivery systems (Gudbergsson et al. 2019). Further evidence for the success of the 
developed method was the fact that the isolated PEVs did separate in different fractions of the 
iodixanol gradient based on their densities and remained functional. The method needs further 
refinement, however.  
 
BDNF is unable to cross the blood-brain barrier and it also has a short half-life (Wurzelmann et al. 
2017). EVs, on the other hand have been shown to cross the blood-brain barrier (Saeedi et al. 2019). 
As they resist complement-mediated lysis (Clayton et al. 2003) EVs thus have the ability to shield their 
cargo and cross the blood-brain barrier. Further and comprehensive study is needed but by this logic 
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there is potential in employing EV as therapeutic agents in BDNF-related neural disorders. Peripheral 
BDNF, on the other hand, is hypothesised to have great potential as a biomarker when diagnosing and 
treating depression and coronary heart disease (Serra-Millá 2016, Amadio et al. 2019). It must, 
however, be taken into consideration that standardised methods for handling of BDNF as a reliable 
biomarker do, as of yet, not exist.  
 
In conclusion, BDNF is central to several physiological and pathophysiological processes. The results 
presented in this thesis are encouraging for future research of what the adaptions of BDNF packed 
PEVs might have to offer . Much more research is necessary but at the same time further research will 
potentially result in new, exciting and meaningful discoveries regarding PEVs, peripheral BDNF and our 
health. 
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Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.  
― Marie Curie 
